NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) — Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today announced that Columbia University (“Columbia”) will present a complete analysis of cardiac data from the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the […]